1-(4-methoxyphenyl)-3-[(2-oxoindol-3-yl)amino]urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-methoxyphenyl)-3-[(2-oxoindol-3-yl)amino]urea
• 化学式: C₁₆H₁₄N₄O₃
• 分子量: 310.312
• InChiKey: DWILXHGVWJPXOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.17
• 重原子数：
  23.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  91.82
• 氢给体数：
  3.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1-(4-methoxyphenyl)-3-[(2-oxoindol-3-yl)amino]urea 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(4-methoxyphenyl)-3-[(2-oxoindol-3-yl)amino]urea
  参考文献：
  名称：

  Isatin N -phenylsemicarbazone：取代基和浓度对阴离子感测选择性和灵敏度的影响†

  摘要：

  取代基和浓度对阴离子传感选择性和九个新的靛红容易地合成灵敏度的效果Ñ -phenylsemicarbazone Ë异构体传感器IIIA-XIa的进行了研究。为缔合常数之间的显着差异IIIA-XIa的具有强和弱碱性阴离子相互作用允许的F检测-或CH 3 COO -的阴离子，即使在高的弱碱性阴离子过量。异丁嗪环的5位取代环和苯环上对环的对位取代会影响传感器：阴离子络合物的化学计量，进而影响传感器的灵敏度。检出限3–4×10-7摩尔分米-3与F -和CH 3 COO -由传感器阴离子IVA和Va的轴承吸电子取代基是在有机溶剂中这些阴离子的最低公布检测限之间。高选择性和传感器的灵敏度经由允许自信˚F -在耐受氟化物的饮用水电平检测。溶液稀释导致传感器选择性的巨大变化。因此，一种E-异构体可用于感测强碱性和弱碱性阴离子。在另一侧上，传感器更高的溶液浓度增加在F -和CH 3COO -阴离子的检测范围中，类似于附加Ž

  DOI：

  10.1039/c4ra04847d
• 作为产物：
  描述：

  4-methoxyphenylcarbamic chloride 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 1-(4-methoxyphenyl)-3-[(2-oxoindol-3-yl)amino]urea
  参考文献：
  名称：

  Isatin N -phenylsemicarbazone：取代基和浓度对阴离子感测选择性和灵敏度的影响†

  摘要：

  取代基和浓度对阴离子传感选择性和九个新的靛红容易地合成灵敏度的效果Ñ -phenylsemicarbazone Ë异构体传感器IIIA-XIa的进行了研究。为缔合常数之间的显着差异IIIA-XIa的具有强和弱碱性阴离子相互作用允许的F检测-或CH 3 COO -的阴离子，即使在高的弱碱性阴离子过量。异丁嗪环的5位取代环和苯环上对环的对位取代会影响传感器：阴离子络合物的化学计量，进而影响传感器的灵敏度。检出限3–4×10-7摩尔分米-3与F -和CH 3 COO -由传感器阴离子IVA和Va的轴承吸电子取代基是在有机溶剂中这些阴离子的最低公布检测限之间。高选择性和传感器的灵敏度经由允许自信˚F -在耐受氟化物的饮用水电平检测。溶液稀释导致传感器选择性的巨大变化。因此，一种E-异构体可用于感测强碱性和弱碱性阴离子。在另一侧上，传感器更高的溶液浓度增加在F -和CH 3COO -阴离子的检测范围中，类似于附加Ž

  DOI：

  10.1039/c4ra04847d

文献信息

• [EN] THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY<br/>[FR] THIOSEMICARBAZONES À ACTIVITÉ ANTI-MDR1
  申请人：US HEALTH

  公开号：WO2012033601A1

  公开（公告）日：2012-03-15

  Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the structure;Formula (I). Examples of the disclosed compounds have been found to have, inter alia, efficacy in directly treating multidrug resistant cells, rendering multidrug resistant cells susceptible to other chemotherapeutics and in some instances reversing multidrug resistance.

  本文披露了具有MDR逆转活性的药物化合物，因此对多药耐药细胞有效。本文披露的示例化合物具有下列结构；公式（I）。已发现披露的化合物的示例具有直接治疗多药耐药细胞的功效，使多药耐药细胞对其他化疗药物敏感，并在某些情况下逆转多药耐药。
• Synthesis, Activity, and Pharmacophore Development for Isatin-β-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells
  作者：Matthew D. Hall、Noeris K. Salam、Jennifer L. Hellawell、Henry M. Fales、Caroline B. Kensler、Joseph A. Ludwig、Gergely Szakács、David E. Hibbs、Michael M. Gottesman

  DOI：10.1021/jm800861c

  日期：2009.5.28

  We have recently identified a new class of compounds that selectively kill cells that express P-glycoprotein (P-gp, MDR1), the ATPase efflux pump that confers multidrug resistance on cancer cells. Several isatin-beta-thiosemicarbazones from our initial study have been validated and a range of analogues synthesized and tested. A number demonstrated improved MDR1-selective activity over the lead, NSC73306 (1). Pharmacophores for cytotoxicity and MDR1 selectivity were generated to delineate the structural features required for activity. The MDR1-selective pharmacophore highlights the importance of aromatic/hydrophobic features at the N4 position of the thiosemicarbazone and the reliance on the isatin moiety as key bioisosteric contributors. Additionally, a quantitative structure-activity relationship (QSAR) model that yielded a cross-validated correlation coefficient of 0.85 effectively predicts the cytotoxicity of untested thiosemicarbazones. Together, the models serve as effective approaches for predicting structures with MDR1-selective activity and aid in directing the search for the mechanism of action of 1.
• Synthesis, In-vitro evaluation and molecular docking studies of oxoindolin phenylhydrazine carboxamides as potent and selective inhibitors of ectonucleoside triphosphate diphosphohydrolase (NTPDase)
  作者：Saira Afzal、Mariya al-Rashida、Abdul Hameed、Julie Pelletier、Jean Sévigny、Jamshed Iqbal

  DOI：10.1016/j.bioorg.2021.104957

  日期：2021.7
• COMPOUNDS WITH MDR1-INVERSE ACTIVITY
  申请人：Hall Matthew D.

  公开号：US20100316655A1

  公开（公告）日：2010-12-16

  Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the structure: Examples of the disclosed compounds have been found to have, inter alia, efficacy in directly treating multidrug resistant cells, rendering multidrug resistant cells susceptible to other chemotherapeutics and in some instances reversing multidrug resistance.
• [EN] COMPOUNDS WITH MDR1-INVERSE ACTIVITY<br/>[FR] COMPOSÉS À ACTIVITÉ MDR1 INVERSE
  申请人：US GOV HEALTH & HUMAN SERV

  公开号：WO2009102433A2

  公开（公告）日：2009-08-20

  Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the following structure: (I). Examples of the disclosed compounds have been found to have, inter alia, efficacy in directly treating multidrug resistant cells, rendering multidrug resistant cells susceptible to other chemotherapeutics and in some instances reversing multidrug resistance.